Development of lentiviral vectors for antiangiogenic gene delivery

Toshiaki Shichinohe, Bernard H. Bochner, Kazuo Mizutani, Miyako Nishida, Susan Hegerich-Gilliam, Luigi Naldini, Noriyuki Kasahara

Research output: Contribution to journalArticlepeer-review


Growth and metastasis of malignant tumors requires angiogenesis. Inhibition of tumor-induced angiogenesis may represent an effective cytostatic strategy. We have constructed recombinant self-inactivating lentiviral vectors expressing angiostatin and endostatin, and have tested their antiangiogenic activities. As VSV-G-pseudotyped lentiviral vectors showed low relative transduction titers on bovine aortic and human umbilical vein endothelial cells, it was difficult to achieve significant inhibition of endothelial cell growth by lentivirus-mediated antiangiogenic gene transfer directly to endothelial cells without concomitant vector-associated cytotoxicity. However, lentivirus vectors could efficiently and stably transduce T24 human bladder cancer cells that are relatively resistant to adenovirus infection due to loss of coxsackievirus-adenovirus receptor expression. Long-term expression and secretion of angiostatin and endostatin from lentivirus-transduced T24 cells resulted in significant inhibition of cellular proliferation on coculture with endothelial cells. This report represents the first use of lentivirus-based vectors to deliver the antiangiogenic factors, angiostatin and endostatin, and suggests the potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of cancer.

Original languageEnglish
Pages (from-to)879-889
Number of pages11
JournalCancer Gene Therapy
Issue number11
Publication statusPublished - 2001


  • Angiostatin
  • Endostatin
  • Lentivirus
  • Vector

ASJC Scopus subject areas

  • Cancer Research
  • Genetics


Dive into the research topics of 'Development of lentiviral vectors for antiangiogenic gene delivery'. Together they form a unique fingerprint.

Cite this